 |
인쇄하기
취소
|
KFDA approves sorafenib for treatment of hepatocellular carcinoma
Bayer HealthCare announced on March 18 that the Korea Food and Drug Administration has approved its new drug application for an indication for sorafenib (Nexavar) in hepatocellular carcinoma.
The oral multikinase inhibitor sorafenib significantly extended overall survival by 44 percent, compared with placebo in patients with hepatocellular carcinoma in a phase III trial in the plenary sessio...
The oral multikinase inhibitor sorafenib significantly extended overall survival by 44 percent, compared with placebo in patients with hepatocellular carcinoma in a phase III trial in the plenary sessio...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.